Abstract
Germline missense mutations in the tyrosine kinase domain of the hepatocyte growth factor / scatter factor (HGF / SF) receptor, c-Met, are thought to be responsible for hereditary papillary renal carcinoma (HPRC) type 1, a form of human kidney cancer. In addition to extensive linkage analysis of HPRC families localizing the HPRC type 1 gene within chromosome 7, the demonstration that individual c-Met mutations reconstituted in cultured cells display enhanced and dysregulated kinase activity, and confer cell transformation and tumorigenicity in mice, solidifies this conclusion. Our prior knowledge of HGF / SF biology and c-Met signaling enabled rapid progress in unraveling the molecular pathogenesis of HPRC type 1, and in laying the framework for the development of novel therapeutics for the treatment of this cancer. At the same time, the study of HPRC type 1 has refined our appreciation of the oncogenic potential of c-Met signaling, and challenges our current understanding of HGF / SF and c-Met function in health and disease.
Keywords: c-met, hgf/sf, hprc, missense mutations, renal carcinoma
Current Molecular Medicine
Title: Hereditary Papillary Renal Carcinoma Type I
Volume: 4 Issue: 8
Author(s): Pathirage G. Dharmawardana, Alessio Giubellino and Donald P. Bottaro
Affiliation:
Keywords: c-met, hgf/sf, hprc, missense mutations, renal carcinoma
Abstract: Germline missense mutations in the tyrosine kinase domain of the hepatocyte growth factor / scatter factor (HGF / SF) receptor, c-Met, are thought to be responsible for hereditary papillary renal carcinoma (HPRC) type 1, a form of human kidney cancer. In addition to extensive linkage analysis of HPRC families localizing the HPRC type 1 gene within chromosome 7, the demonstration that individual c-Met mutations reconstituted in cultured cells display enhanced and dysregulated kinase activity, and confer cell transformation and tumorigenicity in mice, solidifies this conclusion. Our prior knowledge of HGF / SF biology and c-Met signaling enabled rapid progress in unraveling the molecular pathogenesis of HPRC type 1, and in laying the framework for the development of novel therapeutics for the treatment of this cancer. At the same time, the study of HPRC type 1 has refined our appreciation of the oncogenic potential of c-Met signaling, and challenges our current understanding of HGF / SF and c-Met function in health and disease.
Export Options
About this article
Cite this article as:
Dharmawardana G. Pathirage, Giubellino Alessio and Bottaro P. Donald, Hereditary Papillary Renal Carcinoma Type I, Current Molecular Medicine 2004; 4(8) . https://dx.doi.org/10.2174/1566524043359674
DOI https://dx.doi.org/10.2174/1566524043359674 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Metabolomic Heterogeneity of Urogenital Tract Cancers Analyzed by Complementary Chromatographic Techniques Coupled with Mass Spectrometry
Current Medicinal Chemistry ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Current Medicinal Chemistry Phage Display Derived Therapeutic Antibodies
Current Pharmaceutical Biotechnology Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry Reproducibility of Volumetric Assessment of the Inner Ear Using Three Dimensional Reconstruction of the High Resolution MR Sequence
Current Medical Imaging Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature
Reviews on Recent Clinical Trials The Correspondence Between Magnetic Resonance Images and the Clinical and Intraoperative Status of Patients with Spinal Tumors
Current Medical Imaging Subject Index Volume 2
Medicinal Chemistry Radiolabeled Oligonucleotides for Antisense Imaging
Current Organic Synthesis Targeted Therapies in the Treatment of Renal Cell Carcinoma
Current Medicinal Chemistry Imaging Requirements for Personalized Medicine: The Oncologists Point of View
Current Pharmaceutical Design Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets Angiotensin II Regulates Vascular and Endothelial Dysfunction: Recent Topics of Angiotensin II Type-1 Receptor Signaling in the Vasculature
Current Vascular Pharmacology Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Recent Advances in Herbal Nanomedicines for Cancer Treatment
Current Molecular Pharmacology VEGF/VEGFR2 Autocrine Signaling Stimulates Metastasis in Prostate Cancer Cells
Current Angiogenesis (Discontinued) Tyrosine Kinase Mutations in Human Cancer
Current Molecular Medicine Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Predictive Biomarkers and Novel Targets in the Treatment of Metastatic Renal Cell Carcinoma
Current Medicinal Chemistry